Shares of Radius Health Inc. (NASDAQ:RDUS) have earned an average rating of “Buy” from the eleven research firms that are covering the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $63.51.

RDUS has been the subject of a number of research analyst reports. Jefferies Group reiterated a “hold” rating and set a $46.00 price target on shares of Radius Health in a report on Tuesday, September 20th. Canaccord Genuity set a $85.00 target price on Radius Health and gave the company a “buy” rating in a report on Monday, September 19th. HC Wainwright raised their target price on Radius Health from $55.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday, September 21st. Cowen and Company restated a “buy” rating on shares of Radius Health in a report on Wednesday, September 28th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $70.00 target price on shares of Radius Health in a report on Friday, August 5th.

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its stake in shares of Radius Health by 1.1% in the third quarter. Principal Financial Group Inc. now owns 5,616 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 63 shares during the period. BlackRock Group LTD raised its stake in shares of Radius Health by 1.0% in the third quarter. BlackRock Group LTD now owns 18,671 shares of the biopharmaceutical company’s stock valued at $1,010,000 after buying an additional 183 shares during the period. Fifth Third Bancorp raised its stake in shares of Radius Health by 6.2% in the second quarter. Fifth Third Bancorp now owns 3,421 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 201 shares during the period. BlackRock Inc. raised its stake in shares of Radius Health by 10.3% in the third quarter. BlackRock Inc. now owns 3,145 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 293 shares during the period. Finally, Sei Investments Co. raised its stake in shares of Radius Health by 17.8% in the third quarter. Sei Investments Co. now owns 2,082 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 314 shares during the period.

Radius Health (NASDAQ:RDUS) opened at 52.84 on Friday. Radius Health has a one year low of $24.75 and a one year high of $75.50. The firm has a 50-day moving average of $49.44 and a 200-day moving average of $45.02. The company’s market capitalization is $2.28 billion.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by $0.04. During the same period last year, the firm posted ($0.68) earnings per share. On average, analysts anticipate that Radius Health will post ($4.06) earnings per share for the current year.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.